21 November 2016


("Sareum" or "the Company")

Notice of AGM

The Company announces that a notice has been sent to its shareholders to convene its Annual General Meeting ("AGM") which is to be held at 10.00 a.m. on 15 December 2015 at the offices of WH Ireland Limited, 24 Martin Lane, London EC4R 0DR.

Further to the announcement of the Company's final results for the year ended 30 June 2016 released on 2 November 2016, the Company announces that the report and accounts have been posted to those shareholders that requested hard copies.

In addition, an e mail has been sent to both shareholders that have opted for electronic communication and beneficial owners of shares with information rights informing them, inter alia, that the report and accounts are now available on the Company's website.

The notice of AGM and the aforementioned e mail are also available on the Company's website www.sareum.com.

For further information:

Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)


Claire Noyce / William Lynne

020 3764 2341/2342

The Communications Portfolio (Sareum Media enquiries)


Ariane Comstive

07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk